Acute Myeloid Leukemia – Current Treatment – Current Treatment: Physician Insights
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Historically, the prognosis has been poor. Chemotherapy backbones have long dominated treatment, but there is an ongoing shift toward the use of targeted therapies. Their approval has broadened the current treatment arsenal, which now includes the CD33-targeting antibody-drug conjugate Mylotarg (Pfizer), the BCL-2-targeting agent Venclexta (AbbVie / Genentech), the SHH inhibitor Daurismo (Pfizer), and the IDH2 inhibitor Idhifa (Servier / Bristol Myers Squibb). In July 2023, the FDA approved Daiichi Sankyo’s Vanflyta for FLT3-mutation-positive AML. It now competes directly with Rydapt (Novartis) in the newly diagnosed intensive induction setting. Additionally, the December 2022 approval of the IDH1 inhibitor Rezlidhia (Rigel Pharmaceuticals) has had an impact on the market through its direct competition with Tibsovo (Servier) in the relapsed/refractory (R/R) setting.
Questions answered
- How has the entry of Vanflyta and Rezlidhia affected surveyed hematologist-oncologists’ prescribing decisions?
- How does physician prescribing of current treatments vary based on genetic mutation?
- How do drug-treatment rates vary across AML settings?
- What are the main obstacles to prescribing Tibsovo, Idhifa, and Rezlidhia for R/R AML with IDH1/2 mutations?
- What are the key prescribing drivers and obstacles facing therapies such as Vyxeos and Onureg?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand uses that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 U.S. hematologist-oncologists
Key drugs covered: Daurismo, Idhifa, Mylotarg, Onureg, Rezlidhia, Rydapt, Tibsovo, Vanflyta, Venetoclax, Vyxeos, Xospata
